Barclays PLC Actinium Pharmaceuticals, Inc. Transaction History
Barclays PLC
- $854 Billion
- Q3 2025
A detailed history of Barclays PLC transactions in Actinium Pharmaceuticals, Inc. stock. As of the latest transaction made, Barclays PLC holds 4 shares of ATNM stock, worth $5. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4
Previous 2,508
99.84%
Holding current value
$5
Previous $4,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding ATNM
# of Institutions
64Shares Held
6.8MCall Options Held
42.3KPut Options Held
0-
Black Rock Inc. New York, NY1.88MShares$2.44 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.38MShares$1.8 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny625KShares$812,1060.0% of portfolio
-
Acadian Asset Management LLC Boston, MA490KShares$636,4500.0% of portfolio
-
Geode Capital Management, LLC Boston, MA328KShares$426,9440.0% of portfolio
About Actinium Pharmaceuticals, Inc.
- Ticker ATNM
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,184,700
- Market Cap $32.7M
- Description
- Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...